Trial Profile
Phase II Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 25 Feb 2019 Status changed from active, no longer recruiting to completed.
- 10 Jul 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017.
- 13 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jun 2017.